NCT05095519View on ClinicalTrials.gov

Hepatocellular Carcinoma Imaging Using PSMA PET/CT

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 8, 2021

Primary Completion Date

March 8, 2026

Study Completion Date

September 8, 2026

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

18F-DCFPyL

18F-DCFPyL will be administered with a single dose of 3.5 MBq per kg (2-4 MBq per kg), maximum 400 MBq), administered as a slow (over 30 seconds) intravenous injection

Trial Locations (4)

3000

Peter MacCallum Cancer Centre, Melbourne

3065

St Vincent's Hospital, Fitzroy

3084

Austin Health, Heidelberg

Unknown

The Royal Melbourne Hospital, Melbourne

All Listed Sponsors
lead

Peter MacCallum Cancer Centre, Australia

OTHER